Rituximab infection risk under the microscope
NCT ID NCT03778840
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study followed 73 people with autoimmune diseases like rheumatoid arthritis or multiple sclerosis who were starting treatment with rituximab. The goal was to track how many developed serious infections and to understand what factors increase that risk. Researchers also looked at whether giving intravenous immunoglobulins could help prevent infections. The findings may help doctors use rituximab more safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rituximab
- What this could lead to
- If successful, this could help doctors better predict and prevent serious infections in patients taking rituximab for autoimmune diseases.
- What could go wrong
- This is an observational study, not a treatment trial. It aims to gather data, not test a new therapy, so it won't directly change care yet.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Claude Huriez, CHU
Lille, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Strumming for the brain: could ukulele lessons sharpen minds in MS?
- Could music be medicine for the injured brain?
- Can engineered immune cells tame autoimmune disease?
- Blood test may spot hidden nerve damage behind chronic constipation
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Could a metabolic modulator help people with type 1 diabetes use insulin better?